nal pain. A retrospective database, containing preoperative characteristics, radiosurgical dosimetry, and clinical and neuroimaging follow-up data, was established and maintained throughout this period. Surgical pathological examination was used to confirm the histological features of tumors in 3 patients, whereas 18 of 21 patients (9 with meningiomas, 9 with schwannomas) underwent GKS as a primary treatment and the tumors were classified on the basis of the imaging characteristics alone. Tumors were located in the cavernous sinus in 7 cases and the posterior fossa in 19. The mean pain duration before GKS was 22 months (range 3 months-10 years). The mean age at the time of GKS was 54.4 years (range 18-79 years).
Eight patients suffered persistent or recurrent pain after their first GKS procedure and 7 were retreated at the trigeminal root or gasserian ganglion, whereas 1 patient had repeated GKS of the tumor for recurrent pain. The patient characteristics, before and after GKS, are summarized in Table 1 .
Radiosurgical Procedure
In all 21 patients, the Leksell stereotactic coordinate frame was applied after the patients received a local anesthetic supplemented with a mild sedative. Stereotactic Gd-enhanced MR imaging (with 1-mm slice intervals obtained with a volume acquisition) was performed during radiosurgery for target coordinate determination and dose planning. The 201-source Co Gamma Knife unit was used for radiosurgery. The radiation volume was determined and shaped to the tumor margin in all 21 patients by using an average of 13 isocenters (range 2-24 isocenters). For meningiomas, the mean treatment volume was 8.2 ml (range 1.1-21 ml), and the mean tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy). The 50% isodose was selected for most patients. In 7 patients, 5 with meningiomas and 2 with schwannomas, the ipsilateral trigeminal nerve (5 cases) or ganglion (2 cases) was identified, and a mean dose of 60.7 Gy (range 40-70 Gy) was delivered to these targets, which is lower than in idiopathic trigeminal neuralgia considering the additive effect from previous tumor doses (Fig. 1) . Corticosteroid drugs were administered perioperatively in all patients. One patient with meningioma was retreated at the tumor site for recurrent pain even though there was improvement after the first treatment.
Evaluation of Outcomes and Statistical Analysis
We subdivided the clinical outcomes into 4 categories: excellent, good, fair, and poor. Complete pain relief without the use of any medication was defined as an excellent outcome. Patients with complete pain relief but who were still using some medication were considered to have a good outcome. Patients with partial pain relief (> 50% pain relief) were considered to have a fair outcome. No pain relief or < 50% was considered to reflect a poor outcome. Criteria for improvement included a reduction in both the frequency and severity of pain. Various possible factors related to pain prognosis were analyzed with the chi-square test or unconditional logistic regression test.
Results
The follow-up period was 37-97 months (mean 57.8 months). Patient outcomes are detailed in Table 1 . Overall, 12 (57%) of 21 patients experienced an excellent outcome after the first GKS. Cessation of medication occurred at a mean follow-up of 10.5 months (range 2-24 months). One patient (5%) had a good outcome. Initial pain improvement was noted in 17 patients (81%) at a mean of 3.7 months (range 1 week-10 months) after the GKS.
Eight patients had the GKS repeated because of persistent pain (4 cases) and recurrent pain (4 cases). Four patients (50%) had complete pain relief but 1 patient suffered from intractable pain and underwent open surgery to decompress the nerve roots ( Table 2 ). The final results of the first and the repeated GKS procedures were excellent in 16 patients (76%), and there was only 1 patient in whom treatment was considered a failure (Table 3) .
Follow-up MR imaging revealed tumor growth control in all 21 patients at a mean of 46 months after GKS. Seventeen tumors (80%) were smaller than at the time of GKS.
Three of 6 patients with pre-GKS facial numbness reported improvement of numbness intensity, but 4 patients suffered from new facial numbness after the GKS was repeated on the trigeminal nerve or ganglion. Facial numbness did not worsen in anyone after the first GKS.
Other possible factors, including sex, tumor type, pain pattern, tumor site, treatment volume, and previous numbness, were not related to the outcome of GKS for complete pain relief ( Table 4 ). The only statistically significant related factor was tumor volume shrinkage (p = 0.0495).
Discussion
Most trigeminal pain is thought to be idiopathic, but in some cases tumors affect the trigeminal nerve. Barker et al. 1 found that tumors constituted 2.1% of the total series of 1211 nontumor patients. Cheng et al. 5 reported trigeminal neuralgia in 2% and facial pain in 10% of their 2972 patients. These data are roughly equivalent to the 10% found in our series; 21 patients presented with facial pain of 205 patients treated with GKS. Young et al. 19 reported 9 (15%) of 60 patients with facial pain in their study. Trigeminal neuralgia due to tumors is more frequently represented in radiosurgical series than usual, most likely reflecting bias of the referral base.
Meningiomas and schwannomas are the most common tumors to cause facial pain. In all published radiosurgical series, 4, 16, 17, 19 52% of tumors related to facial pain are meningiomas-and 32% of schwannomas are mostly of vestibular origin. In microsurgical series, 1, 3 43% have meningiomas and 33% have schwannomas.
Mechanism of Facial Pain and Pain Relief After GKS
One possible etiological factor to explain trigeminal pain is compression of the nerve root, gasserian gan-glion, or peripheral branches by a tumor. Most authors have found that there is no vascular compression of the entry root or tic douloureux caused by direct compression of cerebellopontine angle tumors. Nijesohn et al. 15 have demonstrated that half of the patients with Meckel cave meningiomas had typical trigeminal neuralgia and there was an excellent prognosis after tumor removal. Bullitt et al. 3 have established that involvement of the cranial nerve V at the trigeminal site influences trigeminal nerve symptoms and signs. Peripherally placed tumors tend to cause atypical facial pain. Middle fossa tumors may present as trigeminal neuralgia but usually cause severe atypical pain, and posterior fossa tumors are most likely to cause typical trigeminal neuralgia.
Microsurgical resection renders a favorable result with rapid debulking to relieve pressure on the ganglion or trigeminal root. As for radiosurgery, we observed that some patients experienced complete pain relief after marked shrinkage of the tumor volume, and the time interval of pain relief could last as long as 24 months. In most patients, however, initial pain improvement was faster than the tumor reduction, so the pain relief mechanism from GKS, in cases of idiopathic trigeminal neuralgia, must play an important role. Radiation block of ephaptic transmission for idiopathic trigeminal neuralgia also serves as an explanation for the relief of tic douloureux after GKS. Kondziolka et al. 9 have observed nerve necrosis after radiation delivery of 100 Gy in a ba- * Cess = cessation; CS = cavernous sinus; E = excellent; F = fair; FU = follow-up; G = good; Imp = improvement; M = meningioma; NC = no change; P = poor; PF = posterior fossa; PTN = painful trigeminal neuropathy; Rx = treatment; S = schwannoma; TN = trigeminal neuralgia; ↓ = 25-50% volume reduction; ↓↓ = >50% volume reduction; � = not present; � = present. boon model. They found that all irradiated nerves exhibited axonal degeneration and mild edema with remnants of some myelinated axons after radiosurgery (80 or 100 Gy). They maintained that pain relief was achieved by partial axon degeneration with remaining intact axons, thus providing preserved facial sensation. The maximal dose for idiopathic trigeminal neuralgia is approximately 70-90 Gy, which is much higher than that for tumors (26-32 Gy). One could argue that the volume of demyelination of the nerves in tumors is probably larger than in idiopathic trigeminal neuralgia, as is the volume of radiation during treatment. The dose threshold for pain relief may be lower in tumor condition. We found that multiple 4-mm shots covered the long stretched speculated myelinated root with a lower dose of 50-60 Gy for idiopathic trigeminal neuralgia by a huge tortuous offending vessel also obtained excellent results.
Another possible etiological factor for trigeminal neuralgia, in tumor patients as well as in nontumor patients, is contact of the trigeminal nerve root with a blood vessel. Jannetta 8 proposed that tumors frequently appeared to have pushed the distorted trigeminal root into an artery that the nerve otherwise would not have been in contact with, or it appeared to have pushed an artery or vein directly into the nerve. He reported on 21 patients with posterior fossa tumors. During surgery, the nerve root entry zone was inspected and found to be compressed by an artery, a vein, or both. 1 They believe that relief of tic douloureux after a tumor resection that did not include a pain relief procedure may be the result of trauma to the nerve during the tumor resection, which routinely and unavoidably causes more nerve trauma than microvascular decompression in patients without tumors. 1 We observed in 1 of our patients with recurrent trigeminal neuralgia that only after tumor shrinkage was there relief of pressure on the entry zone; an offending artery was clearly seen compressing the nerve root (Fig. 2) .
From our experience with microsurgical patients, we believe that tumor shrinkage may help with the relief of tic douloureux. Even though tumor shrinkage takes a longer period for tumors treated with GKS, we observed that the pain relief time might extend to 24 months. Nevertheless, pain relief precedes tumor shrinkage in most patients, so the blockage of demyelination of the nerve root must play an important role in these patients. Ac- cording to this assumption, 7 patients later received nerve root or ganglion irradiation (50-70 Gy) and had a good pain relief outcome.
Outcomes After Radiosurgery and Microsurgery
Tumor removal is by far the most effective means of relieving trigeminal neuralgia in patients who can undergo such a procedure safely. According to Cheng et al., 5 of 25 patients in whom a tumor was removed, 23 (92%) experienced complete pain relief. Barker et al. 1 reported that 19 (82.6%) of 23 patients had excellent long-term results and were pain free at a mean follow-up of 9 years. Bullitt et al. 3 noted that 8 (80%) of 10 patients had a good postoperative recovery after the resection of benign middle or posterior fossa tumors. They have also suggested that the prognosis for pain relief after the removal of a benign tumor is better in trigeminal neuralgia than in cases of atypical facial pain, but this was not observed in our radiosurgical group or that of Pollock et al. 16 In the literature, 4 radiosurgery groups have reported the results (Table 5 ) of benign tumor-associated trigeminal neuralgia or trigeminal pain. 4, 16, 17, 19 Pain relief without medicine in these radiosurgical series ranged from 23.7 to 78.4%, which is relatively inferior to that achieved in microsurgical groups, and the pain control rate was also relatively lower that than seen in idiopathic trigeminal neuralgia cases. 1, 3, 5 However, our results showed that repeated GKS of the trigeminal root or ganglion root could enhance the efficacy of complete pain relief without medication-from 57 to 76.2%-if the nerve root or ganglion was visible and a suitable target; likewise, repeated treatment for intractable idiopathic trigeminal neuralgia had enhanced results. 6 The time interval between the first and second GKS procedure was as long as 3-4 years, and this also reflects that pain relief via medication will inevitably fail. Additionally only long-term observation can reveal the final results. Our excellent pain outcome is similar to that reported by Regis et al., 17 but instead of our secondstage boost their strategy was to use a higher dose to the trigeminal nerve root the first time.
Cranial nerve morbidity, such as new facial numbness, is rarely in radiosurgery groups treating skull base tumors. 6, 14, 17 We also found this to be true in treatment of patients with trigeminal schwannomas, 7 but in our series, 4 patients (50%) developed hypesthesia after GKS was repeated; this incidence was relatively higher than that in the first treatment. It probably reflects destructive character of radiation to cure pain just as our repeated treatment for idiopathic trigeminal neuralgia. 6 
Conclusions
Gamma Knife surgery can be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth, especially in meningiomas and schwannomas. Repeated GKS of the trigeminal root or ganglion can enhance the efficacy of pain management if pain persists or recurs, but subsequent facial numbness is relatively high so the exact dose for treatment needs further investigation. 
